Vaishali Pharma working capital

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

	15.75×	15.75×
	163.57×	163.57×
	81.26×	81.26×
	98.06×	98.06×
	1.67×	1.68×
	0.93×	0.93×
	0.10×	0.10×
	0.11×	0.11×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VAISHALI₹6.87

Vaishali Pharma Limited

· Unclassified

₹ CrorePeersTEMBO TOTAL OSWALSEEDS GROBTEA BEARDSELL HINDCON CROWN ARTNIRMANMcap ₹44.8 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	—	—	—	15.75	15.75
Receivable Days (DSO)	—	—	—	163.57	163.57
Payable Days (DPO)	—	—	—	81.26	81.26
Cash Conversion Cycle (days)	—	—	—	98.06	98.06
Working Capital Turnover	—	—	—	1.68	1.67
Asset Turnover	—	—	—	0.93	0.93
Cash Conversion (CFO/Net Income)	—	—	—	0.10	0.10
CFO/EBITDA	—	—	—	0.11	0.11

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.